通过计算机断层扫描测量他汀类药物对人类免疫缺陷病毒患者肝脂肪变性的影响。
Statin Effects to Reduce Hepatosteatosis as Measured by Computed Tomography in Patients With Human Immunodeficiency Virus.
作者信息
Lo Janet, Lu Michael T, Kim Elli A, Nou Eric, Hallett Travis R, Park Jakob, Hoffmann Udo, Grinspoon Steven K
机构信息
Department of Medicine, Endocrine Division, Program in Nutritional Metabolism , Massachusetts General Hospital and Harvard Medical School , and.
Department of Radiology, Cardiac PET MR CT Program , Massachusetts General Hospital, and Harvard Medical School , Boston.
出版信息
Open Forum Infect Dis. 2016 Jun 13;3(2):ofw062. doi: 10.1093/ofid/ofw062. eCollection 2016 Apr.
Hepatosteatosis is highly prevalent among patients living with human immunodeficiency virus. In a 1-year, randomized, double-blind trial of atorvastatin or placebo, atorvastatin increased liver/spleen ratio among patients with nonalcoholic fatty liver disease, indicating a reduction in hepatosteatosis. This reduction in hepatosteatosis is associated with reduction in low-density lipoprotein cholesterol with statin therapy.
肝脂肪变性在感染人类免疫缺陷病毒的患者中非常普遍。在一项为期1年的阿托伐他汀或安慰剂随机双盲试验中，阿托伐他汀增加了非酒精性脂肪性肝病患者的肝/脾比值，表明肝脂肪变性有所减轻。肝脂肪变性的这种减轻与他汀类药物治疗使低密度脂蛋白胆固醇降低有关。
Zotero 插件